Timberlyne Therapeutics
Timberlyne Therapeutics is a startup based in the United States, most recent round Series A, 1 tracked investor.
About Timberlyne Therapeutics
Timberlyne Therapeutics is a startup founded in 2025 based in the United States. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing transformational therapies for autoimmune diseases. Its lead program, CM313, is an IgG1 monoclonal antibody targeting CD38, designed to modulate multiple arms of the immune system for rapid and durable responses in conditions like Immune Thrombocytopenia and Systemic Lupus Erythematosus.
Explore Timberlyne Therapeutics's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.